Cargando…
Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology
2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) is a promising tool to support the evaluation of response to either target therapies or immunotherapy with immune checkpoint inhibitors both in clinical trials and, in selected patients, at the single patient’s level. The present review aims to discuss...
Autores principales: | Donegani, Maria Isabella, Ferrarazzo, Giulia, Marra, Stefano, Miceli, Alberto, Raffa, Stefano, Bauckneht, Matteo, Morbelli, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466359/ https://www.ncbi.nlm.nih.gov/pubmed/32722205 http://dx.doi.org/10.3390/medicina56080373 |
Ejemplares similares
-
Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting
por: Ferrarazzo, Giulia, et al.
Publicado: (2021) -
18F-Fluorodeoxyglucose Positron Emission Tomography Tracks the Heterogeneous Brain Susceptibility to the Hyperglycemia-Related Redox Stress
por: Miceli, Alberto, et al.
Publicado: (2020) -
Brain Metabolic Correlates of Persistent Olfactory Dysfunction after SARS-Cov2 Infection
por: Donegani, Maria Isabella, et al.
Publicado: (2021) -
Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?
por: Bauckneht, Matteo, et al.
Publicado: (2017) -
Metabolic signature of hyposmia after mild COVID-19: An [18]F-FDG-pet study
por: Pardini, Matteo, et al.
Publicado: (2021)